 |
 |
Search | |
Vol.37 No.6 contents | Japanese/English |
 |
Full Text of PDF (525K) Article in Japanese |
Analysis of Factors Related to Antibody Titer after BNT162b2 mRNA COVID-19 Vaccine
Kohei MARUYAMA1)2), Ryoko ADACHI2) and Kiyoshi SEKIYA1)3)
1)Department of Infection Control, National Hospital Organization, Sagamihara National Hospital, 2)Department of Pharmacy, National Hospital Organization, Sagamihara National Hospital, 3)Department of Allergy and Respirology, National Hospital Organization, Sagamihara National Hospital
BNT162b2 mRNA COVID-19 vaccine has been shown to be effective in preventing onset of disease, but these effects have been reported to decline over time. On the other hand, postvaccination antibody titers have been suggested to correlate with infection prevention efficacy, but there are few reports on factors affecting antibody titers long after vaccination. We tested staff for antibodies against SARS-CoV-2 spike-protein receptor-binding domain after receipt of the second dose of vaccine. Also, we conducted a retrospective cohort study on factors affecting antibody titer after more than 6 months. Staff who were known to have had COVID-19 in the past and those who were not able to collect information by questionnaire were excluded. In this study, we found that the antibody titer decreased significantly when more than 6 months had passed since receipt of the second dose of vaccine. In the univariate analysis, age, gender, and use of hypertensive agents were found to be factors affecting antibody titer in health-care workers who had been vaccinated for more than 6 months. In addition, age was found to be a factor affecting antibody titer in the multivariate logistic regression analysis. Age is a factor affecting antibody titer not only in Japan but also in overseas reports. The results of this study showed that the decrease in vaccine antibody titer over time was more pronounced in the elderly than in the young, when more than 6 months had elapsed since the second dose of vaccine, suggesting that the vaccine's effectiveness in preventing infection is more susceptible to temporal effects in the elderly.
Key words：COVID-19, SARS-CoV-2, vaccine, antibody titer
e-mail: y071281＠yahoo.co.jp
Received: February 18, 2022
Accepted: July 6, 2022
37 (6)：248─255,2022
 |
| Copyright © 2003 Japanese Society for Infection Prevention and Control All rights reserved. |